Mameghan H, Fisher R
Institute of Oncology and Radiotherapy, Prince of Wales Hospital, Sydney, Australia.
Br J Urol. 1989 Mar;63(3):251-8. doi: 10.1111/j.1464-410x.1989.tb05185.x.
We report the results and complications of treatment in 205 patients with nonmetastatic invasive bladder cancer. Between 1977 and 1982 there were 3 treatment groups: palliative radiotherapy, radical radiotherapy, and pre-operative radiotherapy followed by total cystectomy. Data were complete on each patient until the end of 1985 (minimum follow-up 3 years, median 5.6), when 48 patients were alive without evidence of bladder cancer and 28 had died of intercurrent illness (without clinical evidence of bladder cancer). The overall actuarial 5-year survival rate (death from any cause) was 24%. The 5-year survival rates were 13% for group 1, 25% for group 2 and 38% for group 3. Group 1 patients had a significantly shorter survival. The difference between groups 2 and 3 was not statistically significant. The prognostic factors of significance for survival were clinical stage and ureteric obstruction. Factors such as age, tumour grade and multiplicity were significant when examined singly but not in a multivariate analysis which included stage and ureteric obstruction. The actuarial incidence of all radiotherapy complications in bladder and bowel was 9.4 and 10.5% respectively.
我们报告了205例非转移性浸润性膀胱癌患者的治疗结果及并发症情况。1977年至1982年间,有3个治疗组:姑息性放疗、根治性放疗以及术前放疗后行全膀胱切除术。至1985年底(最短随访3年,中位随访5.6年),每位患者的数据均完整,此时48例患者存活且无膀胱癌证据,28例死于并发疾病(无膀胱癌临床证据)。总体精算5年生存率(任何原因导致的死亡)为24%。第1组的5年生存率为13%,第2组为25%,第3组为38%。第1组患者的生存期明显较短。第2组和第3组之间的差异无统计学意义。对生存有显著意义的预后因素为临床分期和输尿管梗阻。年龄、肿瘤分级和多发性等因素单独检查时有显著意义,但在包含分期和输尿管梗阻的多变量分析中则无显著意义。膀胱和肠道所有放疗并发症的精算发生率分别为9.4%和10.5%。